Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1997-2-27
|
| pubmed:abstractText |
Consecutive patients with non-Hodgkin's lymphoma (NHL, n = 133) or Hodgkin's disease (HD, n = 20) were treated with 12.0 Gy of fractionated total body irradiation, etoposide 60 mg/kg, and CY 100 mg/kg followed by infusion of autologous hematopoietic stem cells. Seventy-nine patients received purged (n = 62) or unpurged BM (n = 17), and 74 received unpurged PBSCs alone (n = 56) or with BM (n = 18). The median day for achieving a sustained granulocyte count of 0.5 x 10(9)/I was 14 range (7-66) for BM recipients and 10 (7-30) for PBSC +/- BM recipients (P = 0.03). A platelet count of 20 x 10(9)/I was achieved at a median of day 24 (6-145) in BM recipients and day 11 (range, 7-56) in PBSC +/- BM recipients (P = 0.007). The median number of platelet units transfused was 86 (0-1432) for BM recipients and 30 (6-786) for PBSC +/- BM recipients (P = 0.001). The median number of hospital days was 36 (10-88) for BM recipients and 27 (14-76) for PBSC +/- BM recipients (P = 0.0001). The unadjusted Kaplan-Meier (KM) estimates of survival, event-free survival (EFS) and relapse at 2 years were 0.57, 0.45 and 0.43 for patients receiving BM and 0.55, 0.36 and 0.59 for patients receiving PBSC +/- BM. After adjusting for confounding variables, the estimated relative risk (RR) of death from any cause was 0.92 (P = 0.75), of relapse was 1.25 (P = 0.39), of non-relapse mortality was 0.71 (P = 0.42) and of mortality and/or relapse was 1.17 (P = 0.48) for patients receiving PBSC +/- BM as compared to BM. For 46 patients with NHL receiving unpurged PBSC alone, the unadjusted KM estimate of relapse was 0.61 compared with 0.48 for 52 comparable patients receiving purged BM, while the RR for relapse for patients receiving unpurged PBSCs was 1.37 (P = 0.33) after adjusting for other significant covariates. These data confirm previous observations that patients who receive PBSC +/- BM have faster engraftment, fewer transfusions and shorter hospital stays than patients who receive only BM. There were no statistically significant differences between the two groups in survival, relapse, death from causes other than relapse and event-free survival.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AppelbaumF RFR,
pubmed-author:BensingerW IWI,
pubmed-author:BrunvandM WMW,
pubmed-author:BucknerC DCD,
pubmed-author:ChaunceyTT,
pubmed-author:CliftR ARA,
pubmed-author:DemirevPP,
pubmed-author:DoseHH,
pubmed-author:FeferAA,
pubmed-author:GordonC RCR,
pubmed-author:HolmbergL ALA,
pubmed-author:LillebyKK,
pubmed-author:MartinP LPL,
pubmed-author:MaziarzR TRT,
pubmed-author:McSweeneyP APA,
pubmed-author:MontgomeryPP,
pubmed-author:PressO WOW,
pubmed-author:RowleyS DSD,
pubmed-author:SandersJ EJE,
pubmed-author:SchiffmanKK,
pubmed-author:SolcJJ,
pubmed-author:StorbRR,
pubmed-author:WeaverC HCH,
pubmed-author:WeidenP LPL,
pubmed-author:ZuckermanNN
|
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
131-41
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8832006-Adolescent,
pubmed-meshheading:8832006-Adult,
pubmed-meshheading:8832006-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8832006-Bone Marrow Purging,
pubmed-meshheading:8832006-Bone Marrow Transplantation,
pubmed-meshheading:8832006-Child,
pubmed-meshheading:8832006-Child, Preschool,
pubmed-meshheading:8832006-Clinical Trials as Topic,
pubmed-meshheading:8832006-Combined Modality Therapy,
pubmed-meshheading:8832006-Cyclophosphamide,
pubmed-meshheading:8832006-Disease-Free Survival,
pubmed-meshheading:8832006-Etoposide,
pubmed-meshheading:8832006-Female,
pubmed-meshheading:8832006-Graft Survival,
pubmed-meshheading:8832006-Hematopoietic Cell Growth Factors,
pubmed-meshheading:8832006-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8832006-Humans,
pubmed-meshheading:8832006-Life Tables,
pubmed-meshheading:8832006-Lymphoma,
pubmed-meshheading:8832006-Male,
pubmed-meshheading:8832006-Middle Aged,
pubmed-meshheading:8832006-Prospective Studies,
pubmed-meshheading:8832006-Transplantation, Autologous,
pubmed-meshheading:8832006-Transplantation Conditioning,
pubmed-meshheading:8832006-Treatment Outcome,
pubmed-meshheading:8832006-Whole-Body Irradiation
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|
| pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|